
Joerg F Schlaak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6940636/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. Nature Medicine, 2000, 6, 583-588.	15.2	1,197
2	Nonâ€alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. International Journal of Cancer, 2011, 128, 2436-2443.	2.3	425
3	Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. Journal of Hepatology, 1995, 22, 226-229.	1.8	343
4	Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology, 2009, 49, 1132-1140.	3.6	294
5	Mutational switch of an IL-6 response to an interferon-Â-like response. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8043-8047.	3.3	258
6	Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology, 2007, 46, 1769-1778.	3.6	256
7	Dengue Virus Inhibits Alpha Interferon Signaling by Reducing STAT2 Expression. Journal of Virology, 2005, 79, 5414-5420.	1.5	227
8	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clinical Gastroenterology and Hepatology, 2016, 14, 875-886.e6.	2.4	217
9	Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology, 2011, 53, 1476-1485.	3.6	182
10	Tollâ€like receptorâ€induced innate immune responses in nonâ€parenchymal liver cells are cell typeâ€specific. Immunology, 2010, 129, 363-374.	2.0	178
11	<scp>IFNâ€Î±</scp> subtypes: distinct biological activities in antiâ€viral therapy. British Journal of Pharmacology, 2013, 168, 1048-1058.	2.7	157
12	Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients. European Journal of Clinical Investigation, 2001, 31, 171-178.	1.7	105
13	Proteomic Differences Between Hepatocellular Carcinoma and Nontumorous Liver Tissue Investigated by a Combined Gel-based and Label-free Quantitative Proteomics Study. Molecular and Cellular Proteomics, 2013, 12, 2006-2020.	2.5	100
14	VEGF is Important for Early Liver Regeneration After Partial Hepatectomy. Journal of Surgical Research, 2007, 138, 291-299.	0.8	99
15	Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clinical and Experimental Immunology, 1999, 115, 42-55.	1.1	96
16	A Combination of α-Fetoprotein and Des-γ-Carboxy Prothrombin Is Superior in Detection of Hepatocellular Carcinoma. Digestion, 2013, 87, 121-131.	1.2	90
17	Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain, Behavior, and Immunity, 2014, 42, 222-231.	2.0	90
18	Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. Journal of Hepatology, 2008, 48, 914-922.	1.8	86

#	Article	IF	CITATIONS
19	The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut, 2010, 59, 1111-1119.	6.1	85
20	In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. Liver International, 2015, 35, 627-635.	1.9	84
21	Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. Journal of Hepatology, 2009, 51, 1037-1045.	1.8	80
22	Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clinical Radiology, 2014, 69, 172-178.	0.5	76
23	Poly(I:C) Treatment Leads to Interferon-Dependent Clearance of Hepatitis B Virus in a Hydrodynamic Injection Mouse Model. Journal of Virology, 2014, 88, 10421-10431.	1.5	75
24	Cell-type and Donor-specific Transcriptional Responses to Interferon-α. Journal of Biological Chemistry, 2002, 277, 49428-49437.	1.6	74
25	Quality of life and psychiatric complications after adult living donor liver transplantation. Liver Transplantation, 2006, 12, 1782-1790.	1.3	74
26	Role of Toll-like receptors in liver health and disease. Clinical Science, 2011, 121, 415-426.	1.8	73
27	Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. Journal of Hepatology, 2012, 57, 522-528.	1.8	69
28	All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells. PLoS ONE, 2015, 10, e0138655.	1.1	69
29	Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS ONE, 2015, 10, e0140909.	1.1	68
30	Diagnosis of biliary strictures after liver transplantation: Which is the best tool?. World Journal of Gastroenterology, 2005, 11, 2945.	1.4	66
31	Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of thein vitroantibody response by interferon gamma. Hepatology, 1999, 29, 238-244.	3.6	65
32	TLR1/2 Ligand–Stimulated Mouse Liver Endothelial Cells Secrete IL-12 and Trigger CD8+ T Cell Immunity In Vitro. Journal of Immunology, 2013, 191, 6178-6190.	0.4	62
33	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. Hepatology, 2012, 56, 444-454.	3.6	61
34	Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cellular Microbiology, 2009, 11, 1624-1637.	1.1	53
35	Individual Profiling of Circulating Tumor Cell Composition and Therapeutic Outcome in Patients with Hepatocellular Carcinoma. Translational Oncology, 2013, 6, 420-428.	1.7	52
36	Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system <i>in vivo</i> and <i>in vitro</i> . International Immunology, 2014, 26, 35-46.	1.8	52

#	Article	IF	CITATIONS
37	Micro <scp>RNA</scp> â€155 controls <scp>T</scp> ollâ€like receptor 3†and hepatitis <scp>C</scp> virusâ€induced immune responses in the liver. Journal of Viral Hepatitis, 2014, 21, 99-110.	1.0	45
38	Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection. Nature Chemical Biology, 2016, 12, 1037-1045.	3.9	45
39	Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncology Letters, 2013, 6, 1707-1712.	0.8	43
40	HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clinical and Experimental Immunology, 1999, 115, 508-514.	1.1	42
41	Concomitant Interferon Alpha Stimulation and TLR3 Activation Induces Neuronal Expression of Depression-Related Genes That Are Elevated in the Brain of Suicidal Persons. PLoS ONE, 2013, 8, e83149.	1.1	40
42	Selective Internal Radiation Therapy of Hepatocellular Carcinoma: Potential Hepatopulmonary Shunt Reduction after Sorafenib Administration. Journal of Vascular and Interventional Radiology, 2012, 23, 949-952.	0.2	38
43	Endoscopic Therapy of Posttransplant Biliary Stenoses After Right-Sided Adult Living Donor Liver Transplantation. Clinical Gastroenterology and Hepatology, 2005, 3, 1144-1149.	2.4	37
44	Hepatitis B Virus Particles Activate Toll‣ike Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes. Hepatology, 2020, 72, 829-844.	3.6	36
45	Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opinion on Drug Discovery, 2012, 7, 597-611.	2.5	35
46	Selection of Donors for Adult Living-Donor Liver Donation: Results of the Assessment of the First 205 Donor Candidates. Psychosomatics, 2008, 49, 143-151.	2.5	34
47	CCL5: A Double-Edged Sword in Host Defense Against the Hepatitis C Virus. International Reviews of Immunology, 2011, 30, 366-378.	1.5	32
48	Interferon-Induced Proteins with Tetratricopeptide Repeats 1 and 2 Are Cellular Factors That Limit Hepatitis B Virus Replication. Journal of Innate Immunity, 2014, 6, 182-191.	1.8	32
49	Tri-Iodothyronine as a Stimulator of Liver Regeneration after Partial and Subtotal Hepatectomy. European Surgical Research, 2007, 39, 58-63.	0.6	31
50	Depression and protective factors of mental health in people with hepatitis C: A questionnaire survey. International Journal of Nursing Studies, 2010, 47, 342-349.	2.5	31
51	A completely foreign receptor can mediate an interferon-gamma-like response. EMBO Journal, 2001, 20, 5431-5442.	3.5	30
52	Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state. International Immunology, 2011, 23, 537-544.	1.8	30
53	Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-α-Related Depression in Hepatitis C Virus Infection. Molecular Neurobiology, 2015, 52, 318-329.	1.9	30
54	The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. Journal of Hepatology, 1999, 30, 353-358.	1.8	29

#	Article	IF	CITATIONS
55	Sendai Virus Targets Inflammatory Responses, as Well as the Interferon-Induced Antiviral State, in a Multifaceted Manner. Journal of Virology, 2003, 77, 7903-7913.	1.5	29
56	Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clinical and Experimental Immunology, 1999, 118, 137-146.	1.1	27
57	Analysis of Gene Expression Using High-Density and IFN-Î ³ -Specific Low-Density cDNA Arrays. Genomics, 2001, 77, 50-57.	1.3	27
58	Azathioprine, Mycophenolate Mofetil, and Methotrexate Specifically Modulate Cytokine Production by T Cells. Annals of the New York Academy of Sciences, 1998, 859, 204-207.	1.8	26
59	Erythropoietin Treatment Improves Liver Regeneration and Survival in Rat Models of Extended Liver Resection and Living Donor Liver Transplantation. Transplantation, 2008, 86, 1578-1585.	0.5	26
60	Selective Internal Radiotherapy (SIRT) of Hepatic Tumors: How to Deal with the Cystic Artery. CardioVascular and Interventional Radiology, 2013, 36, 1015-1022.	0.9	25
61	Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells. Scientific Reports, 2017, 7, 43838.	1.6	24
62	Identification of proteins that mediate the pro-viral functions of the interferon stimulated gene 15 in hepatitis C virus replication. Antiviral Research, 2013, 100, 654-661.	1.9	23
63	Selective Hyper-responsiveness of the Interferon System in Major Depressive Disorders and Depression Induced by Interferon Therapy. PLoS ONE, 2012, 7, e38668.	1.1	23
64	Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells. , 1998, 56, 112-117.		22
65	B Cells in Chronically Hepatitis C Virus-Infected Individuals Lack a Virus-Induced Mutation Signature in the <i>TP53</i> , <i>CTNNB1</i> , and <i>BCL6</i> Genes. Journal of Virology, 2013, 87, 2956-2962.	1.5	22
66	Extent of liver resection modulates the activation of transcription factors and the production of cytokines involved in liver regeneration. World Journal of Gastroenterology, 2008, 14, 7093.	1.4	22
67	Anti-PR-3 antibodies induce endothelial IL-8 release. European Journal of Clinical Investigation, 1999, 29, 973-979.	1.7	21
68	A sensitive and specific bioassay for the detection of human interleukin-10. Journal of Immunological Methods, 1994, 168, 49-54.	0.6	20
69	Antisense Phosphorothioate Oligonucleotides to the p65 Subunit of NF-κB Abrogate Fulminant Septic Shock Induced by S. typhimurium in Mice. Scandinavian Journal of Immunology, 2001, 54, 396-403.	1.3	20
70	Role of circulating tumor cells and cancer stem cells in hepatocellular carcinoma. Hepatology International, 2014, 8, 321-329.	1.9	19
71	A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization. PLoS ONE, 2013, 8, e82225.	1.1	19
72	Proteomeâ€Wide Anti–Hepatitis C Virus (HCV) and Antiâ€HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIV oinfected Patients. Journal of Infectious Diseases, 2010, 202, 894-898.	1.9	18

#	Article	IF	CITATIONS
73	Analysis of U2 Small Nuclear RNA Fragments in the Bile Differentiates Cholangiocarcinoma from Primary Sclerosing Cholangitis and Other Benign Biliary Disorders. Digestive Diseases and Sciences, 2014, 59, 1436-1441.	1.1	18
74	Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen. Scientific Reports, 2016, 6, 24865.	1.6	16
75	Heterogeneous, Longitudinally Stable Molecular Signatures in Response to Interferonâ€Î². Annals of the New York Academy of Sciences, 2009, 1182, 58-68.	1.8	15
76	ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. Journal of Medical Virology, 2012, 84, 1106-1114.	2.5	15
77	Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. Journal of Clinical Pathology, 2016, 69, 619-626.	1.0	15
78	Chronic hepatitis C: the viral load per liver cell before treatment as a new marker to predict long-term response to IFN-α therapy. Journal of Hepatology, 1997, 27, 917-921.	1.8	13
79	High interferonâ€stimulated gene ISGâ€15 expression affects HCV treatment outcome in patients coâ€infected with HIV and HCV. Journal of Medical Virology, 2013, 85, 959-963.	2.5	13
80	Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1. Aids, 2012, 26, 2145-2153.	1.0	11
81	CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferonâ€Î± therapy and tollâ€like receptor 3 signalling. Journal of Viral Hepatitis, 2012, 19, 128-137.	1.0	11
82	IGFBP1in epithelial circulating tumor cells as a potential response marker to selective internal radiation therapy in hepatocellular carcinoma. Biomarkers in Medicine, 2014, 8, 687-698.	0.6	11
83	In vitro and in vivo replication of a chemically synthesized consensus genome of hepatitis B virus genotype B. Journal of Virological Methods, 2015, 213, 57-64.	1.0	11
84	Altered Expression of SHIP, a Toll-like Receptor Pathway Inhibitor, Is Associated With the Severity of Liver Fibrosis in Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2011, 204, 1181-1185.	1.9	10
85	Vascular Endothelial Growth Factor Improves Liver Regeneration and Survival after 90% Hepatectomy in a Rat Model of Diet-Induced Steatosis. Digestion, 2013, 88, 235-242.	1.2	10
86	Vascular endothelial growth factor does not improve liver regeneration and survival after 90% subtotal liver resection. Hepatology Research, 2007, 37, 353-359.	1.8	8
87	Impact of hepatic vein deprivation on liver regeneration and function after major hepatectomy. Langenbeck's Archives of Surgery, 2008, 393, 527-533.	0.8	8
88	No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial. Digestive and Liver Disease, 2013, 45, 323-329.	0.4	7
89	Mycophenolate Mofetil for Treatment of Active Inflammatory Bowel Disease: Clinical and Immunological Studies. Annals of the New York Academy of Sciences, 1998, 859, 315-318.	1.8	6
90	Glycine Pretreatment Ameliorates Liver Injury After Partial Hepatectomy in the Rat. Journal of Investigative Surgery, 2010, 23, 12-20.	0.6	6

#	Article	IF	CITATIONS
91	Intrahepatic <scp>B</scp> â€cell follicles of chronically hepatitis <scp>C</scp> virusâ€infected individuals lack signs of an ectopic germinal center reaction. European Journal of Immunology, 2014, 44, 1842-1850.	1.6	6
92	Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon- $\hat{l}\pm$ plus ribavirin. European Journal of Clinical Investigation, 2003, 33, 628-629.	1.7	4
93	Cytokine/chemokine patterns connect host and viral characteristics with clinics during chronic hepatitis C. European Journal of Medical Research, 2012, 17, 9.	0.9	4
94	Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients. Journal of Medical Virology, 2014, 86, 1323-1331.	2.5	4
95	Antiviral Toll-like Receptor Signaling in Non-Parenchymal Liver Cells Is Restricted to TLR3. Viruses, 2022, 14, 218.	1.5	4
96	Rapid development of Epstein–Barr virus-associated Hodgkin's disease after cessation of foscarnet therapy in an HIV-infected patient. International Journal of STD and AIDS, 2000, 11, 609-610.	0.5	3
97	Arterioportal Fistula Complicating Endoscopic Retrograde Cholangiography. Endoscopy, 2005, 37, 93-94.	1.0	3
98	Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection. The Clinical Investigator, 1994, 72, 1030-1036.	0.6	2
99	Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. , 2010, 129, 363.		1
100	How long to treat chronic hepatitis B virus infection with lamivudine?. Journal of Hepatology, 2000, 33, 343.	1.8	0
101	The role of the innate immune system of the liver in the control of HBV and HCV. Virologica Sinica, 2008, 23, 116-123.	1.2	0